The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy -- and those who won't. The latest trial results extend the test's reach.
The companies tout the deal as expanding Exact's commercial footprint to 90 countries and creating a leader in the cancer diagnostic space with projected 2020 revenues of $1.6 billion.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The South San Francisco company intends to use the funding to launch its pivotal trial for its blood-based colorectal cancer screening and submit its test for parallel review for CMS coverage.
The company has a 10,000-patient prospective trial with Geisinger fully enrolled to test CancerSEEK, a test developed at Johns Hopkins University.
Healthy.io's urinalysis testing kit - dubbed Dip.io - uses disposable strips and cups in conjunction with a smartphone camera to read and interpret results.
At Mayo's recently-concluded Transform conference, speakers highlighted a DNA-based stool test that shown to dramatically increase compliance to colon cancer screening.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The Securities & Exchange Commission charges Brett Cohen and David Meyers in an alleged insider trading scheme involving shares of Exact Sciences Corp. and Sequenom Inc. that netted more than $600,000. The federal Securities & Exchange Commission charged a Baltimore business consultant and his uncle in Cleveland of an insider trading scheme that netted the […]
Exact Sciences Corp. (NASDAQ: EXAS) filed a shelf registration statement for the sale of up to $150 million in equity, debt and warrants, according to the federal Securities and Exchange Commission.